GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Lev Pharmaceuticals (LEVP) [hlAlert]

Rating:
Buy LEVP
up 6.00 %

Lev Pharmaceuticals (LEVP) rated Buy

Posted on: Thursday,  Sep 27, 2007  9:25 AM ET by CIBC Wrld Mkts

CIBC Wrld Mkts rated Buy Lev Pharmaceuticals (LEVP) on 09/27/2007, when the stock price was $1.50. Since
then, Lev Pharmaceuticals has gained 6.00% as of 07/22/2008's recent price of $1.59.
If you would have followed this CIBC Wrld Mkts's recommendation on LEVP, you would have gained 6% of your investment in 299 days.

Lev Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's C1 inhibitor, proposed to be marketed as Cinryze, has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Lev has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role

CIBC World Markets strives to deliver leading edge investment research to investing clients through our multi-faceted, firm-wide research product offering. Our research has consistently been recognized as a top research source for its breadth of coverage, industry knowledge and quality of work in generating profitable and timely investment ideas. We provide in-depth coverage for all of the major sectors of the Canadian economy and select coverage of U.S. companies. Our analytical teams remain committed to identifying trends early and developing exploitable investment opportunities across the market capitalization spectrum. With the continued growth in quantitative and computerized investing strategies, we have also developed leading edge quantitative and technical research products to partner with our fundamental approach. Our products are available through several automated avenues: email, website, and third-party market vendors. Client service is our driving force and we constantly advance in offering greater product customization options.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/27/2007 9:25 AM Buy
None
1.50 3.00
as of 5/23/2009
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy